<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type='text/xsl' href='../../ld2webpage.xsl'?>
<LOBBYINGDISCLOSURE2>
  <imported>Y</imported>
  <pages>5</pages>
  <submitURL>
  </submitURL>
  <organizationName>Capitol Hill Consulting Group</organizationName>
  <prefix>
  </prefix>
  <firstName>
  </firstName>
  <lastName>
  </lastName>
  <registrantDifferentAddress>N</registrantDifferentAddress>
  <address1>499 South Capitol Street, SW</address1>
  <address2>Suite 608</address2>
  <city>Washington</city>
  <state>DC</state>
  <zip>20003</zip>
  <zipext>
  </zipext>
  <country>USA</country>
  <principal_city>
  </principal_city>
  <principal_state>
  </principal_state>
  <principal_zip>
  </principal_zip>
  <principal_zipext>
  </principal_zipext>
  <principal_country>
  </principal_country>
  <contactIntlPhone>
  </contactIntlPhone>
  <selfSelect>N</selfSelect>
  <clientName>Endo Pharmaceuticals</clientName>
  <clientGovtEntity>N</clientGovtEntity>
  <senateID>72053-1005228</senateID>
  <houseID>358430091</houseID>
  <reportYear>2016</reportYear>
  <reportType>Q1</reportType>
  <terminationDate>
  </terminationDate>
  <noLobbying>
  </noLobbying>
  <income>50000.00</income>
  <expenses>
  </expenses>
  <expensesMethod>
  </expensesMethod>
  <printedName>Tazeen Ahmad</printedName>
  <signedDate>4/15/2016 1:10:51 PM</signedDate>
  <alis>
    <ali_info>
      <issueAreaCode>HCR</issueAreaCode>
      <specific_issues>
        <description>Issues relating to prescription drug abuse.
Issues relating to incentives for tamper-resistant formulations.
Issues relating to FDA approvals of new drugs and generic drugs.
Issues related to the FDA
Issues related to Opioids
Issues relating to Medicare Part D rebates.
House 21st Century Cures bill (Senate companion which includes NIH and FDA issues)
H.R.471, S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015
Issues relating to the labeling of generic drugs.
Issues relating to CDC guidance for prescribing opioids
S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act
Issues relating to products containing high doses of acetaminophen.
Issues relating to the labeling of generic drugs.
Issues relating to removal of FDA unapproved products from the market
S. 524 the Comprehensive Addiction and Recovery Act and related legislation H.R. 4641.
</description>
      </specific_issues>
      <federal_agencies>U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES</federal_agencies>
      <lobbyists>
        <lobbyist>
          <lobbyistFirstName>David</lobbyistFirstName>
          <lobbyistLastName>Jory</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Brian</lobbyistFirstName>
          <lobbyistLastName>Sutter</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>Staff Dir., W&amp;M Health Subcommittee, Chrman Dave Camp April'13-Dec.'14
Professional Staff, W&amp;M Health Subcommittee, Chrman Dave Camp, Jan'11-April'13
Leg Dir. Rep. Dave Camp, May'08-Jan'11
Leg Asst Rep. Dave Camp, Feb'03-May'08; Staff Ast July'02</coveredPosition>
          <lobbyistNew>Y</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>William Steve</lobbyistFirstName>
          <lobbyistLastName>Southerland</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>William Steve Southerland, II served as the U.S. Representative for Florida's 2nd congressional district from 2011 to 2015.</coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
      </lobbyists>
      <foreign_entity_issues>
      </foreign_entity_issues>
    </ali_info>
    <ali_info>
      <issueAreaCode>PHA</issueAreaCode>
      <specific_issues>
        <description>Issues related to tamper resistant formulation of pharmaceutical and generic drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825</description>
      </specific_issues>
      <federal_agencies>U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES</federal_agencies>
      <lobbyists>
        <lobbyist>
          <lobbyistFirstName>David</lobbyistFirstName>
          <lobbyistLastName>Jory</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Brian</lobbyistFirstName>
          <lobbyistLastName>Sutter</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>Staff Dir., W&amp;M Health Subcommittee, Chrman Dave Camp April'13-Dec.'14
Professional Staff, W&amp;M Health Subcommittee, Chrman Dave Camp, Jan'11-April'13
Leg Dir. Rep. Dave Camp, May'08-Jan'11
Leg Asst Rep. Dave Camp, Feb'03-May'08; Staff Ast July'02</coveredPosition>
          <lobbyistNew>Y</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>William Steve</lobbyistFirstName>
          <lobbyistLastName>Southerland</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>William Steve Southerland, II served as the U.S. Representative for Florida's 2nd congressional district from 2011 to 2015.</coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
      </lobbyists>
      <foreign_entity_issues>
      </foreign_entity_issues>
    </ali_info>
    <ali_info>
      <issueAreaCode>TAX</issueAreaCode>
      <specific_issues>
        <description>H.R. 160- Protect Medical Innovation Act of 2015
Issues relating to incentives for life sciences research
Tax treatment of inverted companies
Tax issues on mergers and acquisitions
</description>
      </specific_issues>
      <federal_agencies>U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES</federal_agencies>
      <lobbyists>
        <lobbyist>
          <lobbyistFirstName>David</lobbyistFirstName>
          <lobbyistLastName>Jory</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Brian </lobbyistFirstName>
          <lobbyistLastName>Sutter</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>Staff Dir., W&amp;M Health Subcommittee, Chrman Dave Camp April'13-Dec.'14
Professional Staff, W&amp;M Health Subcommittee, Chrman Dave Camp, Jan'11-April'13
Leg Dir. Rep. Dave Camp, May'08-Jan'11
Leg Asst Rep. Dave Camp, Feb'03-May'08; Staff Ast July'02-</coveredPosition>
          <lobbyistNew>Y</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>William Steve </lobbyistFirstName>
          <lobbyistLastName>Southerland</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>William Steve Southerland, II served as the U.S. Representative for Florida's 2nd congressional district from 2011 to 2015.</coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
      </lobbyists>
      <foreign_entity_issues>
      </foreign_entity_issues>
    </ali_info>
  </alis>
  <updates>
    <clientAddress>
    </clientAddress>
    <clientCity>
    </clientCity>
    <clientState>
    </clientState>
    <clientZip>
    </clientZip>
    <clientZipext>
    </clientZipext>
    <clientCountry>
    </clientCountry>
    <prinClientCity>
    </prinClientCity>
    <prinClientState>
    </prinClientState>
    <prinClientZip>
    </prinClientZip>
    <prinClientZipext>
    </prinClientZipext>
    <prinClientCountry>
    </prinClientCountry>
    <generalDescription>
    </generalDescription>
    <inactive_lobbyists>
      <inactive_lobbyist>
        <firstName>
        </firstName>
        <lastName>
        </lastName>
        <suffix>
        </suffix>
      </inactive_lobbyist>
      <inactive_lobbyist>
        <firstName>
        </firstName>
        <lastName>
        </lastName>
        <suffix>
        </suffix>
      </inactive_lobbyist>
      <inactive_lobbyist>
        <firstName>
        </firstName>
        <lastName>
        </lastName>
        <suffix>
        </suffix>
      </inactive_lobbyist>
      <inactive_lobbyist>
        <firstName>
        </firstName>
        <lastName>
        </lastName>
        <suffix>
        </suffix>
      </inactive_lobbyist>
    </inactive_lobbyists>
    <inactive_ALIs>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
    </inactive_ALIs>
    <affiliatedUrl>
    </affiliatedUrl>
    <affiliatedOrgs>
      <affiliatedOrg>
        <affiliatedOrgName>
        </affiliatedOrgName>
        <affiliatedOrgAddress>
        </affiliatedOrgAddress>
        <affiliatedOrgCity>
        </affiliatedOrgCity>
        <affiliatedOrgState>
        </affiliatedOrgState>
        <affiliatedOrgZip>
        </affiliatedOrgZip>
        <affiliatedOrgCountry>
        </affiliatedOrgCountry>
        <affiliatedPrinOrgCity>
        </affiliatedPrinOrgCity>
        <affiliatedPrinOrgState>
        </affiliatedPrinOrgState>
        <affiliatedPrinOrgCountry>
        </affiliatedPrinOrgCountry>
      </affiliatedOrg>
      <affiliatedOrg>
        <affiliatedOrgName>
        </affiliatedOrgName>
        <affiliatedOrgAddress>
        </affiliatedOrgAddress>
        <affiliatedOrgCity>
        </affiliatedOrgCity>
        <affiliatedOrgState>
        </affiliatedOrgState>
        <affiliatedOrgZip>
        </affiliatedOrgZip>
        <affiliatedOrgCountry>
        </affiliatedOrgCountry>
        <affiliatedPrinOrgCity>
        </affiliatedPrinOrgCity>
        <affiliatedPrinOrgState>
        </affiliatedPrinOrgState>
        <affiliatedPrinOrgCountry>
        </affiliatedPrinOrgCountry>
      </affiliatedOrg>
    </affiliatedOrgs>
    <inactiveOrgs>
      <inactiveOrgName>
      </inactiveOrgName>
      <inactiveOrgName>
      </inactiveOrgName>
      <inactiveOrgName>
      </inactiveOrgName>
    </inactiveOrgs>
    <foreignEntities>
      <foreignEntity>
        <name>
        </name>
        <address>
        </address>
        <city>
        </city>
        <state>
        </state>
        <country>
        </country>
        <prinCity>
        </prinCity>
        <prinState>
        </prinState>
        <prinCountry>
        </prinCountry>
        <contribution>
        </contribution>
        <ownership_Percentage>
        </ownership_Percentage>
      </foreignEntity>
    </foreignEntities>
    <inactive_ForeignEntities>
      <inactive_ForeignEntity>
      </inactive_ForeignEntity>
      <inactive_ForeignEntity>
      </inactive_ForeignEntity>
      <inactive_ForeignEntity>
      </inactive_ForeignEntity>
      <inactive_ForeignEntity>
      </inactive_ForeignEntity>
      <inactive_ForeignEntity>
      </inactive_ForeignEntity>
      <inactive_ForeignEntity>
      </inactive_ForeignEntity>
    </inactive_ForeignEntities>
  </updates>
</LOBBYINGDISCLOSURE2>